RT Journal Article
SR Electronic
T1 New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31<sup>st</sup>Annual Meeting of the Society for Immunotherapy of Cancer, 2016
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP 50
DO 10.1186/s40425-017-0253-2
VO 5
IS 1
A1 Prasad S. Adusumilli
A1 Edward Cha
A1 Mark Cornfeld
A1 Thomas Davis
A1 Adi Diab
A1 Thomas W. Dubensky, Jr.
A1 Elizabeth Evans
A1 Jane L. Grogan
A1 Bryan A. Irving
A1 Rom S. Leidner
A1 Shane A. Olwill
A1 Patrick Soon-Shiong
A1 Frederic Triebel
A1 David Tuck
A1 Adrian Bot
A1 Roger D. Dansey
A1 Charles G. Drake
A1 Gordon J. Freeman
A1 Ramy Ibrahim
A1 Salil Patel
A1 Daniel S. Chen
YR 2017
UL http://jitc.bmj.com/content/5/1/50.abstract
AB This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy.Abbreviations:AEAdverse event(s)APCAntigen presenting cell(s)CARChimeric antigen receptor(s)CITNCancer Immunotherapy Trials NetworkCRCColorectal cancerDCDendritic cell(s)DLTDose-limiting toxicityDNRDominant negative receptorEGFREpidermal growth factor receptorFDAFood and Drug AdministrationHNSCCHead and neck squamous cell carcinomaIDOIndoleamine 2,3-dioxygenaseIHCImmunohistochemistryKIRKiller cell immunoglobulin-like receptor(s)LADDLive-attenuated double-deleted Listeria monocytogenesmAbMonoclonal antibodyMDSCMyeloid-derived suppressor cell(s)MHCMajor histocompatibility complexMSSMicrosatellite stableNKNatural killerNSCLCNon-small cell lung cancerPBMCPeripheral blood mononuclear cellsPFSProgression-free survivalPRPartial responseRCCRenal cell carcinomaSEMA4DSemaphorin 4DSITCSociety for Immunotherapy of CancerTCBT cell-engaging bispecific antibodiesTEAETreatment-emergent adverse event(s)TILTumor infiltrating lymphocyte(s)TLRToll-like receptorTMETumor microenvironmentTregRegulatory T cell(s)